Cargando…

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo

Respiratory syncytial virus (RSV) infection is a leading cause of hospitalization and mortality in young children. Protective therapy options are limited. Currently, palivizumab, a monoclonal IgG1 antibody, is the only licensed drug for RSV prophylaxis, although other IgG antibody candidates are bei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobino, Shamir R., Nederend, Maaike, Reijneveld, J. Frederiek, Augustijn, Daan, Jansen, J. H. Marco, Meeldijk, Jan, Reiding, Karli R., Wuhrer, Manfred, Coenjaerts, Frank E. J., Hack, C. Erik, Bont, Louis J., Leusen, Jeanette H. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939987/ https://www.ncbi.nlm.nih.gov/pubmed/29553863 http://dx.doi.org/10.1080/19420862.2018.1433974

Ejemplares similares

Bovine IgG Prevents Experimental Infection With RSV and Facilitates Human T Cell Responses to RSV
por: Nederend, Maaike, et al.
Publicado: (2020)

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
por: Meyer, Saskia, et al.
Publicado: (2015)

Specificity and Effector Functions of Human RSV-Specific IgG from Bovine Milk
por: den Hartog, Gerco, et al.
Publicado: (2014)

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season
por: Fernández, Pilar, et al.
Publicado: (2010)

The N-Glycosylation of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and Strains
por: de Haan, Noortje, et al.
Publicado: (2017)

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
por: Evers, Mitchell, et al.
Publicado: (2020)

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
por: Mejías, Asunción, et al.
Publicado: (2007)

Differences in IgG Fc Glycosylation Are Associated with Outcome of Pediatric Meningococcal Sepsis
por: de Haan, Noortje, et al.
Publicado: (2018)

Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro
por: Könitzer, Jennifer D., et al.
Publicado: (2015)

MALDI-TOF-MS reveals differential N-linked plasma- and IgG-glycosylation profiles between mothers and their newborns
por: Jansen, Bas C., et al.
Publicado: (2016)

Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health
por: Plomp, Rosina, et al.
Publicado: (2017)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG
por: Brandsma, Arianne M., et al.
Publicado: (2019)

One-step zero-background IgG reformatting of phage-displayed antibody fragments enabling rapid and high-throughput lead identification
por: Chen, Chao-Guang, et al.
Publicado: (2014)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Immunoglobulin G (IgG) Fab Glycosylation Analysis Using a New Mass Spectrometric High-throughput Profiling Method Reveals Pregnancy-associated Changes
por: Bondt, Albert, et al.
Publicado: (2014)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

IgG3 Snitcher of RSV Infections in the Very Young
por: Schepens, Bert, et al.
Publicado: (2017)

Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
por: Stewart, Dan L, et al.
Publicado: (2013)

External validation and update of a prognostic model to predict mortality in hospitalized adults with RSV: A retrospective Dutch cohort study
por: Vos, Laura M., et al.
Publicado: (2019)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

The Level and Duration of RSV-Specific Maternal IgG in Infants in Kilifi Kenya
por: Ochola, Rachel, et al.
Publicado: (2009)

Advances in the Production and Batch Reformatting of Phage Antibody Libraries
por: Reader, Rose H., et al.
Publicado: (2019)

The high resource impact of reformatting requirements for scientific papers
por: Jiang, Yan, et al.
Publicado: (2019)

IgA EGFR antibodies mediate tumour killing in vivo
por: Boross, Peter, et al.
Publicado: (2013)

Local IL-17A Potentiates Early Neutrophil Recruitment to the Respiratory Tract during Severe RSV Infection
por: Stoppelenburg, Arie Jan, et al.
Publicado: (2013)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

CONNJUR spectrum translator: an open source application for reformatting NMR spectral data
por: Nowling, Ronald J., et al.
Publicado: (2011)

An Automated Approach to Efficiently Reformat a Large Collection of Compounds
por: Cui, Jimmy, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0h52cbigpsvvaol9i8ftvmggn0